Aptabio Receives Approval for Phase 2 Clinical Trial of Contrast Agent-Induced Kidney Injury Treatment

Aptabio announced on the 2nd that it has received approval from the Ministry of Food and Drug Safety for the Phase 2 clinical trial plan (IND) of Isuzinaxib (APX-115), a treatment for contrast-induced acute kidney injury (CI-AKI), in South Korea.

The clinical trial will be conducted at 12 hospitals in Korea and the United States, targeting patients with contrast-induced acute kidney injury. The purpose of the clinical trial is to evaluate the safety of orally administered APX-115 compared to placebo in patients undergoing PCI (percutaneous coronary intervention).

This content was produced with the assistance of AI translation services.